hyperlipoproteinaemia type 1
Metabolic · 2015–2022
3decisions
3medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| triglycerides, medium chain Ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency; and dietary management of conditions requiring… | Mar 2022 | Recommended | none received |
| triglycerides, long chain; triglycerides, medium chain Ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency (long chain); dietary management of conditions… | Mar 2017 | Recommended | no section in document |
| triglycerides medium chain formula Hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, chylous ascites, and chylothorax. | Nov 2015 | Recommended | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.